NSAID Interaction Risks
NSAIDs interact with antihypertensives, anticoagulants, and nephrotoxic drugs through prostaglandin inhibition. These interactions are among the most common in clinical practice.
## Mechanism of NSAID Interactions
NSAIDs inhibit cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Prostaglandins regulate renal blood flow, platelet aggregation, and gastric mucosal protection. Blocking these pathways creates interaction potential with numerous drug classes.
## NSAIDs and Antihypertensives
Prostaglandins promote renal sodium excretion and vasodilation. NSAIDs blunt these effects, increasing blood pressure by an average of 3-5 mmHg. This antagonizes the action of:
- **ACE inhibitors and ARBs** — most susceptible; NSAIDs reduce their antihypertensive and renal protective effects
- **Diuretics** — NSAIDs reduce natriuretic response, particularly of loop and thiazide diuretics
- **Beta-blockers** — modest attenuation of antihypertensive effect
The "triple whammy" combination of NSAID + ACE inhibitor/ARB + diuretic increases acute kidney injury risk by 31% compared to ACE/ARB + diuretic alone. This combination should be avoided, especially in elderly patients and those with pre-existing CKD.
## NSAIDs and Anticoagulants
NSAIDs increase bleeding risk through two independent mechanisms:
1. **COX-1 inhibition** — impairs platelet thromboxane A2 production, reducing aggregation
2. **GI mucosal damage** — creates bleeding sites in the stomach and duodenum
Combined with warfarin, DOACs, or antiplatelet agents, the bleeding risk is synergistic. Ibuprofen specifically interferes with low-dose aspirin's antiplatelet effect by competing for the COX-1 binding site; if ibuprofen is taken first, aspirin cannot achieve irreversible platelet inhibition.
## NSAIDs and Lithium
NSAIDs reduce renal lithium clearance by 15-25%, raising serum lithium levels into the toxic range. The mechanism involves NSAID-mediated reduction in GFR and enhanced proximal tubular lithium reabsorption. All NSAIDs except aspirin and sulindac carry this risk. Lithium levels should be monitored within 5-7 days of starting or stopping an NSAID.
## NSAIDs and Methotrexate
NSAIDs decrease methotrexate renal clearance, potentially causing pancytopenia and mucositis. The interaction is most dangerous with high-dose methotrexate (oncology doses) but clinically relevant even at low rheumatologic doses. Patients on weekly methotrexate should use NSAIDs cautiously with monitoring.
## NSAIDs and Nephrotoxic Agents
| Combination | Additional Risk |
|-------------|----------------|
| NSAID + aminoglycoside | Synergistic nephrotoxicity |
| NSAID + cyclosporine/tacrolimus | Additive renal vasoconstriction |
| NSAID + contrast dye | Increased contrast nephropathy risk |
| NSAID + tenofovir | Compounded tubular toxicity |
## Safer Alternatives
- **Acetaminophen** — no renal, GI, or antiplatelet effects at recommended doses
- **Topical NSAIDs** (diclofenac gel) — minimal systemic absorption, lower interaction risk
- **Short courses** — 3-5 day NSAID courses pose less risk than chronic use
- **COX-2 selective agents** (celecoxib) — less GI and antiplatelet risk, but equivalent renal and cardiovascular effects
## Key Takeaways
- NSAIDs raise blood pressure 3-5 mmHg and antagonize ACE inhibitors, ARBs, and diuretics
- The NSAID + ACEI/ARB + diuretic "triple whammy" significantly increases AKI risk
- Ibuprofen blocks aspirin's antiplatelet effect if taken first
- NSAIDs raise lithium levels 15-25%; monitor lithium when starting or stopping NSAIDs
- Acetaminophen and topical NSAIDs are safer alternatives for patients on interacting drugs